aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference
aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT„ Study in Pulmonary Sarcoidosis
aTyr Pharma to present at upcoming investor conferences.
aTyr Pharma announces first quarter 2024 results and provides corporate update
aTyr Pharma to Participate in April Investor Conferences
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results
aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Tyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT¢ Clinical Trial Participants